Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Jehovah's Witnesses and blood transfusions wikipedia , lookup
Blood donation wikipedia , lookup
Blood transfusion wikipedia , lookup
Autotransfusion wikipedia , lookup
Men who have sex with men blood donor controversy wikipedia , lookup
Rh blood group system wikipedia , lookup
NATIONAL 111S00201 BLOOD COMPONENT DATASHEET PLATELET POOL LEUCOCYTE DEPLETED COMPONENT DESCRIPTION A pool of platelets derived from the buffy coats of four whole blood donations and 6 containing less than 5 x 10 leucocytes per pool. QUALITY SPECIFICATIONS Volume: Leucocyte Count: Platelet Count: CMV Status: High titre anti-A or B: Anticoagulant: pH at out date: Fibrinogen: Factor VIIIc: Supernatant Hb: Haematocrit: 200 - 350 mls <5 x 106 per pool ≥ 2.4 x 1011 per pool On demand Indicated on label if present CPD 6.4 – 7.4 (day 5) N/A N/A N/A N/A USES To provide platelet replacement where quantitative or qualitative deficiency of platelets is causing or may cause a significant haemostatic problem. DOSAGE AND ADMINISTRATION Dosage One unit of platelet pool-leucocyte depleted will result in adequate clinical response in most instances. In some cases more than one unit may be necessary. In patients with increased platelet consumption or destruction the dose is determined by clinical response. Prepared by: Susanta Ghosh Authorised by: Peter Flanagan QA Approved by: Nick Smith Effective Date: 11/01/02 Copy No: Page 1 of 3 File Name: 111S00201 Previous Name: N/A NATIONAL 111S00201 Administration The ABO group of the platelet concentrate should preferably be compatible with that of the patient but this is not essential. Platelet concentrate contains a few red cells and when prepared from Rh(D) positive donors may result in the production of antiRh(D) antibodies in Rh(D) negative patients. Where the product is labelled as Rh(D) Positive and given to an Rh(D) negative female of reproductive years or younger, consideration should be given to prophylaxis with anti-D. Platelets must be transfused intravenously through an infusion set with an in-line 170-200 micron filter. The infusion should generally be completed within 30 minutes. It is a legal requirement that all details of blood component infusion are documented in the patient’s case notes (eg, date and time of issue, product number, ordering medical officer, given by, checked by, time started). CONTRAINDICATIONS, WARNINGS, ADVERSE REACTIONS Contraindications Platelet transfusions have been implicated in severe adverse reactions in patients with thrombotic thrombocytopenic purpura and heparin induced thrombocytopenia. Platelet concentrate may cause adverse reactions particularly to patients with history of non-haemolytic transfusion reactions though this type of reaction is less common with leucodepleted components. Recipients with severe cellular immune-deficiency and those receiving transfusions from related donors should be transfused with irradiated platelets. Warning Acute transfusion reactions may occur if incompatible, wrongly stored or bacterially contaminated platelets are transfused. Non-haemolytic transfusion reactions can present as urticaria, fever and rarely as anaphylaxis. Symptoms include chills, rigors, fever, chest tightness, hypotension. The transfusion should be stopped immediately and the cause investigated. The implicated component should be returned to the blood bank. Prepared by: Susanta Ghosh Authorised by: Peter Flanagan QA Approved by: Nick Smith Effective Date: 11/01/02 Copy No: Page 2 of 3 File Name: 111S00201 Previous Name: N/A NATIONAL 111S00201 Adverse Reactions Immune: Immunisation to leucocyte antigens and platelet antigens can make the patient refractory to subsequent platelet transfusion, though this complication is less frequent than with non-leucodepleted component. Small numbers of red cells present in platelet concentrate may occasionally lead to immunisation to red cell antigens. Transfusion related lung injury might occur if antibodies to recipient’s granulocytes are present in donor plasma. Transfusion of non-irradiated products can cause graft versus host disease in patients with severe cellular immune deficiency or in those receiving transfusion from genetically related donors. Haemodynamic: overload. Transfusion of excessive volumes may lead to circulatory Infective: Every care is taken in donor selection and in blood collection, processing and storage to reduce the risk of infection but there is a small but definite risk of transmitting bacterial, viral and other infections. Platelet pools usually involve exposure to several donors and this may increase the risk of infection. Risk of bacterial contamination is higher with platelets as they are stored at room temperature. Reaction to bacterially contaminated platelets usually develops within minutes and consists of chills, rigors, fever, nausea, vomiting, diarrhea, abdominal and muscle pain, hypotension, haemoglobinaemia and disseminated intravascular coagulation. Recipients showing signs and symptoms consistent with septic reaction should be treated for septic shock before laboratory results are available. Haemostatic failure may develop in these recipients and they may require appropriate support. STORAGE AND PRECAUTIONS Store at 20 °C to 24 °C with agitation. If platelets have been pooled use within 6 hours or within the expiry time stated on the bag. Do not use if the material is clotted or the bag is damaged. Discard all used or partially used bags. All unused bags should be returned to the Blood Bank. Avoid skin contact with this preparation. FURTHER INFORMATION Each unit conforms to the NZBS specification for donor selection and collection procedure. Each unit has tested negative for HBsAg, Anti-HIV-I and -II, anti-HCV and syphilis. This component has also tested negative for HCV and HIV viral RNA using NAT method. Prepared by: Susanta Ghosh Authorised by: Peter Flanagan QA Approved by: Nick Smith Effective Date: 11/01/02 Copy No: Page 3 of 3 File Name: 111S00201 Previous Name: N/A